#161897

TOV-2223G

Cat. #161897

TOV-2223G

Cat. #: 161897

Organism: Human

Tissue: Ovary

Disease: Cancer

£575.00

This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.

Contributor

Inventor: Anne-Marie Mes-Masson and Diane Provencher

Institute: Centre Hospitalier de L’université de Montréal

Primary Citation: Ouellet, et al. 2008. BMC Cancer 28,8:(152). PMID 18507860

Tool Details
Handling
References

Tool Details

*FOR RESEARCH USE ONLY

  • Name: TOV-2223G
  • Organism: Human
  • Tissue: Ovary
  • Donor: Donor was 89 at diagnosis with Stage 3, IIIC ovarian high-grade serous adenocarcinoma. Patient had undergone some pre-treatment prior to speciment collection in 2004. There is also a TP53 Exon 4 mutation
  • Disease: Cancer
  • Morphology: Large cells with cobblestone morphology
  • Growth properties: Mixed
  • Crispr: No
  • Description: Epithelial ovarian cancer cell line derived from poorly differentiated serous solid tumors.
  • Production details: Tumor was macro-dissected onto 100mm petri dish with serum-free OSE medium supplemented with 1000 U of collagenase. Cells were resuspended after several hours into 8ml of medium, divided into four separate 60mm petri dishes and 10% FBS was added
  • Biosafety level: 1

Handling

  • Format: Frozen
  • Growth medium: Serum free OSE medium
  • Temperature: 37° C
  • Atmosphere: 5% CO2 and 5% O2
  • Shipping conditions: Dry Ice
  • Storage conditions: Liquid Nitrogen
  • Cultured in antibiotics: 2.5ug/ml amphotericin B and 50 ug/ml gentamicin
  • Characterisation tests: Immunohistochemistry, Cytogenetics/Spectral Karyotyping, Single-stran conformation polymorphism analysis, etc.
  • Str profiling: TH01: 6,9 / D21S11: 30,31 / D5S818: 12 / D13S317: 11 / D7S820: 12 / D16S539: 10,15 / CSF1PO: 12 / vWA: 17,19 / TPOX: 11 / AMEL: X

References

  • Linh, et al. 2023. Future Sci OA. 29, 9(8):FSO875. PMID: 37621847
  • Sauriol, et al. 2023. Sci Rep. 27, 13(1):3334. PMID: 36849518
  • Sevinyan, et al. 2022. Cancers (Basel). 16, 14(22):5628. PMID:36428724
  • Ouellet, et al. 2008. BMC Cancer 28,8:(152). PMID 18507860